在第一项人体试验中,PromiCell针对前列腺癌的CAR T疗法显示出早期的前景,预计将于2025年1月12日推出. PromiCell's CAR T therapy for prostate cancer shows early promise in first human trial, to be presented Jan. 12, 2025.

PromiCell公司宣布,其首席医务官John Lee博士将介绍PRO CAR-201A第一阶段试验的临时结果,PRO CAR-201A是2025年1月12日在旧金山Biotech Chopace Showcase 2026针对STEAP1的抗转移性剖析性前列腺癌的CART细胞疗法。 PromiCell, Inc. announced that its Chief Medical Officer, Dr. John Lee, will present interim results from a Phase 1 trial of PRO CAR-201A, a CAR T cell therapy targeting STEAP1, for metastatic castration-resistant prostate cancer (mCRPC) at Biotech Showcase 2026 in San Francisco on January 12, 2025. 审判正在评估治疗的安全和人类先入为主病人的早期疗效。 The trial is evaluating the treatment’s safety and early efficacy in first-in-human patients. PromiCell正在开发下一代CAR T和TCR T治疗固体和血癌的疗法,旨在克服肿瘤的脱逃和免疫逃避。 PromiCell is developing next-generation CAR T and TCR T therapies for solid and blood cancers, aiming to overcome tumor escape and immune evasion. 该公司设在美国,正在向临床和商业用途推进。 The company, based in the U.S., is advancing its pipeline toward clinical and commercial use.